Form 8-K - Current report:
SEC Accession No. 0001641172-25-020574
Filing Date
2025-07-22
Accepted
2025-07-22 16:14:26
Documents
13
Period of Report
2025-07-18
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K form8-k.htm   iXBRL 8-K 38988
2 EX-4.1 ex4-1.htm EX-4.1 41050
  Complete submission text file 0001641172-25-020574.txt   252401

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE ppcb-20250718.xsd EX-101.SCH 3011
4 XBRL LABEL FILE ppcb-20250718_lab.xml EX-101.LAB 34239
5 XBRL PRESENTATION FILE ppcb-20250718_pre.xml EX-101.PRE 22356
15 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3444
Mailing Address 302/6 BUTLER STREET CAMBERWELL, VICTORIA C3 3124
Business Address 302/6 BUTLER STREET CAMBERWELL, VICTORIA C3 3124 61-03-9882-0780
Propanc Biopharma, Inc. (Filer) CIK: 0001517681 (see all company filings)

EIN.: 330662986 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 8-K | Act: 34 | File No.: 000-54878 | Film No.: 251140456
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)